{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T15:05:56Z","timestamp":1764687956795,"version":"3.41.2"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"1125","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,9,1]]},"abstract":"<jats:sec>\n                  <jats:title>Objectives:<\/jats:title>\n                  <jats:p>Radiation-induced changes (RIC) secondary to focal radiotherapy can imitate tumour progression in brain metastases and make follow-up clinical decision making unreliable. 11C-methyl-L-methionine-PET (MET-PET) is widely used for the diagnosis of RIC in brain metastases, but minimal literature exists regarding the optimum PET measuring parameter to be used. We analysed the diagnostic performance of different MET-PET measuring parameters in distinguishing between RIC and tumour progression in a retrospective cohort of brain metastasis patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods:<\/jats:title>\n                  <jats:p>26 patients with 31 metastatic lesions were included on the basis of having undergone a PET scan due to radiological uncertainty of disease progression. The PET images were analysed and methionine uptake quantified using standardised-uptake-values (SUV) and tumour-to-normal tissue (T\/N) ratios, generated as SUVmean, SUVmax, SUVpeak, T\/Nmean, T\/Nmax-mean and T\/Npeak-mean. Metabolic-tumour-volume and total-lesion methionine metabolism were also computed. A definitive diagnosis of either RIC or tumour progression was established by clinicoradiological follow-up of least 4 months subsequent to the investigative PET scan.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results:<\/jats:title>\n                  <jats:p>All MET-PET parameters except metabolic-tumour-volume showed statistically significant differences between tumour progression and lesions with RIC. Receiver-operating-characteristic curve and area-under the-curve analysis demonstrated the highest value of 0.834 for SUVmax with a corresponding optimum threshold of 3.29. This associated with sensitivity, specificity, positive predictive and negative predictive values of 70.59%, 78.57%, 80.00% and 68.75% respectively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>MET-PET is a useful modality for the diagnosis of RIC in brain metastases. SUVmax was the PET parameter with the greatest diagnostic performance.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Advances in knowledge:<\/jats:title>\n                  <jats:p>More robust comparisons between SUVmax and SUVpeak could enhance follow-up treatment planning.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1259\/bjr.20210275","type":"journal-article","created":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T08:49:41Z","timestamp":1625734181000},"source":"Crossref","is-referenced-by-count":8,"title":["11C-methyl-L-methionine PET measuring parameters for the diagnosis of tumour progression against radiation-induced changes in brain metastases"],"prefix":"10.1093","volume":"94","author":[{"given":"Chris W.","family":"Govaerts","sequence":"first","affiliation":[{"name":"Department of Radiology (EB44), Medical Imaging Centre (MIC), University Medical Centre Groningen, University of Groningen , Groningen , The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bart RJ.","family":"van Dijken","sequence":"additional","affiliation":[{"name":"Department of Radiology (EB44), Medical Imaging Centre (MIC), University Medical Centre Groningen, University of Groningen , Groningen , The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilles N.","family":"Stormezand","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Molecular Imaging, Medical Imaging Centre (MIC), University Medical Centre Groningen, University of Groningen , Groningen , The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiske L.","family":"van der Weide","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, University Medical Centre Groningen, University of Groningen , Groningen , The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michiel","family":"Wagemakers","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, University Medical Centre Groningen, University of Groningen , Groningen , The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roelien H.","family":"Enting","sequence":"additional","affiliation":[{"name":"Department of Neurology, University Medical Centre Groningen, University of Groningen , Groningen , The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anouk","family":"van der Hoorn","sequence":"additional","affiliation":[{"name":"Department of Radiology (EB44), Medical Imaging Centre (MIC), University Medical Centre Groningen, University of Groningen , Groningen , The Netherlands"},{"name":"Brain Tumour Imaging Laboratory, Division of Neurosurgery, Department of Clinical Neuroscience, University of Cambridge, Addenbrooke's Hospital , Cambridge , UK"},{"name":"Department of Radiology, University of Cambridge, Addenbrooke's Hospital , Cambridge , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,8,18]]},"reference":[{"key":"2024050310313552900_b1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41572-018-0055-y","article-title":"Brain metastases","volume":"5","author":"Achrol","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"2024050310313552900_b2","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.trecan.2018.01.003","article-title":"The evolving landscape of brain metastasis","volume":"4","author":"Valiente","year":"2018","journal-title":"Trends Cancer"},{"key":"2024050310313552900_b3","first-page":"4655","article-title":"Recent trends in epidemiology of brain metastases: an overview","volume":"32","author":"Tabouret","year":"2012","journal-title":"Anticancer Res"},{"issue":"Suppl 2","key":"2024050310313552900_b4","first-page":"1","article-title":"The current and future treatment of brain metastases","volume":"3","author":"Hardesty","year":"2016","journal-title":"Front Surg"},{"key":"2024050310313552900_b5","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1093\/neuonc\/now241","article-title":"Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European association of neuro-oncology (EANO","volume":"19","author":"Soffietti","year":"2017","journal-title":"Neuro Oncol"},{"key":"2024050310313552900_b6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fonc.2018.00161","article-title":"Mechanisms and therapy for cancer metastasis to the brain","volume":"8","author":"Franchino","year":"2018","journal-title":"Front Oncol"},{"key":"2024050310313552900_b7","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1016\/S1470-2045(15)70057-4","article-title":"Response assessment criteria for brain metastases: proposal from the RANO group","volume":"16","author":"Lin","year":"2015","journal-title":"Lancet Oncol"},{"key":"2024050310313552900_b8","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.ijrobp.2013.05.015","article-title":"Challenges with the diagnosis and treatment of cerebral radiation necrosis","volume":"87","author":"Chao","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2024050310313552900_b9","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.2217\/fon.13.271","article-title":"Postradiation imaging changes in the CNS: how can we differentiate between treatment effect and disease progression?","volume":"10","author":"Walker","year":"2014","journal-title":"Future Oncol"},{"key":"2024050310313552900_b10","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1148\/radiology.158.1.3940373","article-title":"Brain radiation lesions: MR imaging","volume":"158","author":"Dooms","year":"1986","journal-title":"Radiology"},{"key":"2024050310313552900_b11","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1007\/s12094-017-1816-x","article-title":"Treatment-Related changes in glioblastoma: a review on the controversies in response assessment criteria and the concepts of true progression, pseudoprogression, pseudoresponse and radionecrosis","volume":"20","author":"Delgado-L\u00f3pez","year":"2018","journal-title":"Clin Transl Oncol"},{"key":"2024050310313552900_b12","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/jmri.26171","article-title":"Pseudoprogression of brain tumors","volume":"48","author":"Thust","year":"2018","journal-title":"J Magn Reson Imaging"},{"key":"2024050310313552900_b13","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s11060-017-2375-2","article-title":"Pseudoprogression, radionecrosis, inflammation or true tumor progression? challenges associated with glioblastoma response assessment in an evolving therapeutic landscape","volume":"134","author":"Ellingson","year":"2017","journal-title":"J Neurooncol"},{"key":"2024050310313552900_b14","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3171\/2014.10.JNS141610","article-title":"Adverse radiation effect after stereotactic radiosurgery for brain metastases: incidence, time course, and risk factors","volume":"123","author":"Sneed","year":"2015","journal-title":"J Neurosurg"},{"key":"2024050310313552900_b15","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s00259-012-2295-5","article-title":"Value of 11C-methionine PET in imaging brain tumours and metastases","volume":"40","author":"Glaudemans","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2024050310313552900_b16","doi-asserted-by":"crossref","first-page":"694","DOI":"10.2967\/jnumed.107.048082","article-title":"Diagnostic accuracy of 11C-methionine PET for differentiation of recurrent brain tumors from radiation necrosis after radiotherapy","volume":"49","author":"Terakawa","year":"2008","journal-title":"J Nucl Med"},{"key":"2024050310313552900_b17","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.ijrobp.2010.07.002","article-title":"An interindividual comparison of O-(2-[18F]fluoroethyl)-L-tyrosine (FET)- and L-[methyl-11C]methionine (MET)-PET in patients with brain gliomas and metastases","volume":"81","author":"Grosu","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2024050310313552900_b18","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-017-3702-x","article-title":"Prospective study of 11C-methionine PET for distinguishing between recurrent brain metastases and radiation necrosis: limitations of diagnostic accuracy and long-term results of salvage treatment","volume":"17","author":"Yomo","year":"2017","journal-title":"BMC Cancer"},{"key":"2024050310313552900_b19","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s12149-010-0450-2","article-title":"Semiquantitative analysis of C-11 methionine PET may distinguish brain tumor recurrence from radiation necrosis even in small lesions","volume":"25","author":"Okamoto","year":"2011","journal-title":"Ann Nucl Med"},{"key":"2024050310313552900_b20","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s00259-009-1302-y","article-title":"Clinical impact of (11)C-methionine PET on expected management of patients with brain neoplasm","volume":"37","author":"Yamane","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2024050310313552900_b21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0132515","article-title":"Differentiation of brain tumor recurrence from post-radiotherapy necrosis with 11C-methionine PET: visual assessment versus quantitative assessment","volume":"10","author":"Minamimoto","year":"2015","journal-title":"PLoS One"},{"key":"2024050310313552900_b22","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1007\/s00259-006-0206-3","article-title":"EANM procedure guidelines for brain tumour imaging using labelled amino acid analogues","volume":"33","author":"Vander Borght","year":"2006","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2024050310313552900_b23","first-page":"1501","article-title":"Prognostic value of 11C-methionine PET in patients with IDH wild-type glioma (Abstract","volume":"60","author":"van Dijken","year":"2019","journal-title":"J Nucl Med"},{"key":"2024050310313552900_b24","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1093\/neuonc\/noz003","article-title":"Pet imaging in patients with brain metastasis-report of the RANO\/PET group","volume":"21","author":"Galldiks","year":"2019","journal-title":"Neuro Oncol"},{"key":"2024050310313552900_b25","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1007\/s00259-018-4090-4","article-title":"Serial FLT PET imaging to discriminate between true progression and pseudoprogression in patients with newly diagnosed glioblastoma: a long-term follow-up study","volume":"45","author":"Brahm","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2024050310313552900_b26","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S1470-2045(08)70125-6","article-title":"Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas","volume":"9","author":"Brandsma","year":"2008","journal-title":"Lancet Oncol"},{"key":"2024050310313552900_b27","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.3171\/jns.2003.98.5.1056","article-title":"Methionine positron emission tomography of recurrent metastatic brain tumor and radiation necrosis after stereotactic radiosurgery: is a differential diagnosis possible?","volume":"98","author":"Tsuyuguchi","year":"2003","journal-title":"J Neurosurg"},{"issue":"Suppl 1","key":"2024050310313552900_b28","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00259-017-3740-2","article-title":"EANM\/EARL harmonization strategies in PET quantification: from daily practice to multicentre oncological studies","volume":"44","author":"Aide","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2024050310313552900_b29","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s11060-015-1883-1","article-title":"The use of (18)F-FDG PET to differentiate progressive disease from treatment induced necrosis in high grade glioma","volume":"125","author":"Dankbaar","year":"2015","journal-title":"J Neurooncol"},{"key":"2024050310313552900_b30","doi-asserted-by":"crossref","DOI":"10.1186\/s13550-016-0177-8","article-title":"For avid glucose tumors, the SUV peak is the most reliable parameter for [(18)F]FDG-PET\/CT quantification, regardless of acquisition time","volume":"6","author":"Sher","year":"2016","journal-title":"EJNMMI Res"},{"key":"2024050310313552900_b31","first-page":"281","article-title":"DynamicO-(2-18F-fluoroethyl)-L-tyrosine positron emission tomography differentiates brain metastasis recurrence from radiation injury after radiotherapy","volume":"19","author":"Ceccon","year":"2016","journal-title":"Neuro Oncol"},{"key":"2024050310313552900_b32","doi-asserted-by":"crossref","first-page":"30","DOI":"10.2967\/jnumed.113.121418","article-title":"18F-FDOPA PET for differentiating recurrent or progressive brain metastatic tumors from late or delayed radiation injury after radiation treatment","volume":"55","author":"Lizarraga","year":"2014","journal-title":"J Nucl Med"},{"key":"2024050310313552900_b33","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/1748-717X-6-48","article-title":"Stereotactic radiosurgery for brain metastases: analysis of outcome and risk of brain radionecrosis","volume":"6","author":"Minniti","year":"2011","journal-title":"Radiat Oncol"}],"container-title":["The British Journal of Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjr\/article-pdf\/94\/1125\/20210275\/57393527\/bjr.20210275.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjr\/article-pdf\/94\/1125\/20210275\/57393527\/bjr.20210275.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T10:32:57Z","timestamp":1714732377000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjr\/article\/doi\/10.1259\/bjr.20210275\/7663729"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,18]]},"references-count":33,"journal-issue":{"issue":"1125","published-online":{"date-parts":[[2021,8,18]]},"published-print":{"date-parts":[[2021,9,1]]}},"URL":"https:\/\/doi.org\/10.1259\/bjr.20210275","relation":{},"ISSN":["0007-1285","1748-880X"],"issn-type":[{"type":"print","value":"0007-1285"},{"type":"electronic","value":"1748-880X"}],"subject":[],"published-other":{"date-parts":[[2021,9,1]]},"published":{"date-parts":[[2021,8,18]]},"article-number":"20210275"}}